Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Sane

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
Circulation|July 13, 2006
Angiotensin II type 1 receptor blockade prevents alcoholic cardiomyopathyChe-Ping Cheng, Heng-Jie Cheng, Carol Cunningham, et al.
Plos One|October 15, 2013
Cytoprotective effect of recombinant human erythropoietin produced in transgenic tobacco plantsFarooqahmed S Kittur, Mamudou Bah, Stephanie Archer-Hartmann, et al.
Translational Stroke Research|September 23, 2021
A Novel Plant-Produced Asialo-rhuEPO Protects Brain from Ischemic Damage Without Erythropoietic ActionMaotao He, Farooqahmed S Kittur, Chiu-Yueh Hung, et al.
Journal of Thrombosis and Thrombolysis|August 6, 2005
Safety of abciximab administration during PCI of patients with previous strokeEfthymios N Deliargyris, Bharathi Upadhya, Robert J Applegate, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 27, 2006
Unfractionated heparin reduces the anti-platelet effects of abciximab but not eptifibatide during PCIEfthymios N Deliargyris, Bharathi Upadhya, Laura G Melton, et al.
Journal of Thrombosis and Thrombolysis|April 9, 2005
Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromesMary Ann Mascelli, Efthymios N Deliargyris, Lakshmi V Damaraju, et al.
American Heart Journal|July 29, 2008
Derived fibrinogen compared with C-reactive protein and brain natriuretic peptide for predicting events after myocardial infarction and coronary stentingTerry R Ketch, Samuel J Turner, Matthew T Sacrinty, et al.
Thrombosis Research|April 2, 2008
ABO blood types: influence on infarct size, procedural characteristics and prognosisTerry R Ketch, Samuel J Turner, Matthew T Sacrinty, et al.
Atherosclerosis|February 8, 2005
Mast cell tryptase: a new biomarker in patients with stable coronary artery diseaseEfthymios N Deliargyris, Bharathi Upadhya, David C Sane, et al.
American Heart Journal|December 22, 2005
Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trialVictor L Serebruany, Alex N Pokov, Alex I Malinin, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Circulation|July 13, 2006
Angiotensin II type 1 receptor blockade prevents alcoholic cardiomyopathyChe-Ping Cheng, Heng-Jie Cheng, Carol Cunningham, et al.
Plos One|October 15, 2013
Cytoprotective effect of recombinant human erythropoietin produced in transgenic tobacco plantsFarooqahmed S Kittur, Mamudou Bah, Stephanie Archer-Hartmann, et al.
Translational Stroke Research|September 23, 2021
A Novel Plant-Produced Asialo-rhuEPO Protects Brain from Ischemic Damage Without Erythropoietic ActionMaotao He, Farooqahmed S Kittur, Chiu-Yueh Hung, et al.
Journal of Thrombosis and Thrombolysis|August 6, 2005
Safety of abciximab administration during PCI of patients with previous strokeEfthymios N Deliargyris, Bharathi Upadhya, Robert J Applegate, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 27, 2006
Unfractionated heparin reduces the anti-platelet effects of abciximab but not eptifibatide during PCIEfthymios N Deliargyris, Bharathi Upadhya, Laura G Melton, et al.
Journal of Thrombosis and Thrombolysis|April 9, 2005
Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromesMary Ann Mascelli, Efthymios N Deliargyris, Lakshmi V Damaraju, et al.
American Heart Journal|July 29, 2008
Derived fibrinogen compared with C-reactive protein and brain natriuretic peptide for predicting events after myocardial infarction and coronary stentingTerry R Ketch, Samuel J Turner, Matthew T Sacrinty, et al.
Thrombosis Research|April 2, 2008
ABO blood types: influence on infarct size, procedural characteristics and prognosisTerry R Ketch, Samuel J Turner, Matthew T Sacrinty, et al.
Atherosclerosis|February 8, 2005
Mast cell tryptase: a new biomarker in patients with stable coronary artery diseaseEfthymios N Deliargyris, Bharathi Upadhya, David C Sane, et al.
American Heart Journal|December 22, 2005
Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trialVictor L Serebruany, Alex N Pokov, Alex I Malinin, et al.
Pageof 9